Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

NCT07032727 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Targeted Therapy
IDH1-Mutated Malignancies
Mutations

Interventions

DRUG: Olutasidenib
DRUG: Cladribine (CLAD)
DRUG: Venetoclax
DRUG: Gilteritinib
DRUG: Ruxolitinib
DRUG: Cytarabine

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]